Nutshell Biotech (Shanghai) Co. Ltd. has identified eukaryotic translation initiation factor 4E (eiF4E) inhibitors reported to be useful for the treatment of cancer.
Chinese researchers and their collaborators have published data on the bifunctional antibody JS-201, which exerts dual targeting of PD-1 and TGF-β signaling, for the potential treatment of cancer and its protective role against radiation-induced lung injury.
EMA approval of the Alzheimer’s disease therapy Leqembi (lecanemab) has stalled once again, after the European Commission did not as usual nod through the agency’s recommendation, but told it to examine safety data that have recently become available.
Tensive S.r.l. raised €14 million (US$14.5 million) in a series A financing round for its bio-absorbable breast implant Regenera, for patients undergoing reconstructive surgery after lumpectomy. The funds will be used to complete a pivotal clinical trial to evaluate the safety and performance of the technology.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) and/or KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of cancer.
Dewpoint Therapeutics Inc. has nominated a second development candidate, DPTX-3496. The oral, small-molecule condensate modulator targets β-catenin to address Wnt-driven colorectal cancer, triple-negative breast cancer and non-small-cell lung cancer. IND-enabling studies have commenced, with an IND filing planned in the second half of this year.
Ohio State University has described NADH-ubiquinone oxidoreductase (complex I) inhibitors acting as radiosensitizers for radiation therapy reported to be useful for the treatment of cancer.
Regor Pharmaceuticals Inc. has divulged phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi, skeletal abnormalities and scoliosis, among others.
Marking the second global approval after Japan, the U.S. FDA has approved Datroway (datopotamab deruxtecan), a trophoblast cell surface antigen 2-directed antibody-drug conjugate (ADC) from Daiichi Sankyo Co. Ltd. and Astrazeneca plc, for treating adults with hormone receptor-positive, HER2-negative unresectable or recurrent breast cancer after prior chemotherapy.
